An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

December 25, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

July 31, 2027

Conditions

Advanced Solid Tumors

Interventions

DRUG

SHR-1826

dose is calculated based on the subjects' baseline weight.

Trial Locations (1)

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY